Negatives Priced In; Lithium and Life Sciences to Drive Accelerated Growth

Overview

This report is UBS’s earnings commentary on Sunresin (300487). The core thesis is that market concerns over Q1 earnings missing expectations and weakening lithium prices have already been reflected in the recent ~18% share price correction. However, the company’s strong growth prospects in lithium extraction and life sciences—two high-growth segments—have not yet been priced in. UBS maintains its 'Buy' rating and RMB 90 target price, viewing the current valuation as an attractive entry point.

Core views

The report attributes recent share price pressure to two main factors: (1) Q1 earnings falling short of market expectations, and (2) sustained weakness in lithium prices raising investor concerns about the lithium extraction business outlook. However, after discussions with management, UBS concludes these concerns are 'overblown' and that the company’s growth momentum is actually accelerating. On lithium extraction: The key catalyst is Guoneng Group’s lithium project in Tibet. Unlike previous one-off equipment sales, Sunresin is adopting a 'Build-Own-Operate' (BOO) model for this project, responsible for both construction and long-term operations. Phase I targets annual production of 10,000 tons of lithium hydroxide (LiOH), with the first 3,300-ton line performing well in trial runs. Based on supply chain checks, UBS believes the main hurdle—securing local government production permits—has been cleared, and approval is expected imminently. Financially, Guoneng pays Sunresin a fixed processing fee per ton produced (covering all costs) plus a double-digit percentage of lithium sales revenue. Assuming 5,000 tons sold in 2026 at a lithium price of RMB 150,000/ton, the project could contribute ~RMB 200 million in incremental net profit (excluding the company’s own guidance of RMB 1.1–1.2 billion). Simplified: every 1,000 tons of LiOH sold generates ~RMB 40 million in incremental net profit; at full capacity and a lithium price of RMB 180,000/ton, profit upside could reach ~RMB 450 million. On life sciences: Two major growth drivers are materializing. First, solid-phase synthesis carriers (SPSC) for oligonucleotides: Novartis’s Leqvio (a lipid-lowering drug) saw Q1 2026 sales grow 69% YoY globally (106% ex-U.S., led by China), directly boosting demand for Sunresin’s oligonucleotide SPSC. Sales are projected to jump from RMB 15 million in 2025 to RMB 1 billion in 2026. Second, weight-loss drug SPSC: benefiting from continued strong sales of Eli Lilly’s Mounjaro and Zepbound, as well as Innovent’s Masutide and other generics, 2026 sales are expected to grow 50% YoY to RMB 800 million. Additionally, UBS does not rule out overseas M&A to expand the company’s life sciences export footprint. On valuation: With a 2025–2028E EPS CAGR of 39%, the current share price implies only 23x/17x P/E for 2026E/2027E—significantly undervalued relative to its growth potential. UBS’s three-stage DCF model yields a RMB 90 target price, implying 50% upside.

Analysis framework

The report follows a clear analytical framework: 'Negative factors priced in → Growth engine breakdown → Valuation attractiveness assessment.' First, it identifies the two triggers for the recent share price decline (Q1 miss + falling lithium prices) and then validates—through management discussions and supply chain research—whether these concerns are overdone. For lithium extraction, it uses a semi-quantitative value-chain approach: specific capacity figures (3,300/10,000 tons), lithium price assumptions (RMB 150k/180k per ton), and revenue-sharing terms are used to quantify profit elasticity, making the project’s economic value transparent. For life sciences, it applies a downstream-to-upstream demand transmission model: sales data from Novartis, Eli Lilly, and others are used to forecast demand pull-through for Sunresin’s SPSC products, with concrete volume projections (e.g., oligonucleotide SPSC sales rising from RMB 15M to RMB 1B). Finally, the contrast between high EPS CAGR (39%) and low P/E multiples (23x/17x) supports the 'high growth, low valuation' conclusion, with the three-stage DCF serving as the anchor for the RMB 90 target price.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  Three-Stage DCF Valuation

  DCF estimates a company’s value by discounting its future cash flows to present value. The 'three-stage' approach divides forecasts into 'high growth, decelerating growth, and stable maturity' phases, better reflecting real-world growth trajectories. UBS used this model to derive Sunresin’s RMB 90 target price, implying 50% upside from current levels.

• Industry/Value Chain Analysis FrameworkVolume-price decomposition

  Volume × Price = Revenue; Fixed Processing Fee + Revenue Share = Profit Model

  For the lithium extraction project, the report breaks down profit contribution using 'tons produced × lithium price × revenue share' plus 'fixed processing fees covering costs.' For general readers, this means: project profit = guaranteed base profit from processing fees + variable profit tied to lithium prices. This clarifies how lithium price fluctuations impact profit elasticity.

• Industry/Value Chain Analysis FrameworkDownstream-to-Upstream Transmission

  Downstream Drug Sales → Upstream SPSC Consumables Demand

  In analyzing the life sciences segment, the report links sales growth of end-market drugs (e.g., Novartis’s Leqvio, Eli Lilly’s Mounjaro/Zepbound) to increased demand for Sunresin’s resin-based consumables. This 'strong downstream sales → higher upstream procurement' logic is a classic application of value chain analysis.

• Fundamentals & Financial FrameworkOperating/Financial Leverage Analysis

  Profit Elasticity to Lithium Price and Volume: ~RMB 40M Net Profit per 1,000 Tons of LiOH

  Through volume-price sensitivity analysis, the report quantifies how changes in lithium prices and production volumes affect Sunresin’s net profit. This allows readers to assess 'if lithium prices rise to X level, how much better will earnings be?' rather than relying on a single-point forecast.

• Cyclical & Sentiment FrameworkInflection Point Analysis

  Negatives Already Priced In; Growth Inflection Not Yet Priced In

  A core theme of the report is identifying the 'timing gap' between market sentiment and fundamentals: the market has overreacted to Q1 miss and lithium price pressure (negatives already priced in), but has not yet priced in accelerating earnings growth (from lithium project approval + life sciences ramp-up). This expectation gap creates room for valuation recovery.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sunresin (300487.SS)

  Sole subject of this research report

  Strengths

  Nearly 20 years of manufacturing experience in ion exchange and adsorption separation resins; ~25 product categories and over 200 resin types; Guoneng project’s BOO model ensures recurring processing fees and lithium sales revenue share; life sciences segment (oligonucleotide and weight-loss drug SPSC) shows high growth with >60% gross margins

  Risks

  Lower-than-expected resin refill demand; rising raw material costs squeezing margins; delays in overseas metal extraction projects due to tighter local regulations; global recession risk; delays in lithium extraction project completion or slower-than-expected client acquisition; potential import bans by foreign governments

Key data

• Share Price Correction (Past Month)~18%Attributed mainly to Q1 earnings miss and weakening lithium prices
• 2025–2028E EPS CAGR39%Compound annual growth rate of earnings per share over this period
• 2026E P/E23xCurrent share price of RMB 60 implies 23x 2026E P/E
• 2027E P/E17xCurrent share price of RMB 60 implies 17x 2027E P/E
• 12-Month Target PriceRMB 90Based on three-stage DCF, implying 50% upside
• Guoneng Project Phase I Capacity10,000 tons/year LiOHPilot Line 1 has 3,300-ton capacity and is already in trial operation
• Guoneng Project (2026E Assumption) Incremental Profit~RMB 200 millionBased on 5,000 tons sold at RMB 150,000/ton lithium price; could rise to ~RMB 450 million at full capacity and RMB 180,000/ton
• Oligonucleotide SPSC 2026E SalesRMB 1 billionUp from RMB 15 million in 2025, driven by Novartis Leqvio demand surge
• Weight-Loss Drug SPSC 2026E Growth50% YoYExpected to reach RMB 800 million, driven by Eli Lilly and Innovent product launches
• UBS vs. Consensus EPS (2026E)2.65 vs. 2.27UBS’s earnings forecast is significantly above consensus
• 2025E Net Profit Guidance (Excluding Guoneng)RMB 1.1–1.2 billionGuoneng project profit is incremental to this baseline

Impact & implications

The report sees a clear opportunity for expectation gap closure in Sunresin’s case. The market has overfocused on short-term earnings volatility and lithium price sentiment, overlooking two high-certainty growth engines now materializing: (1) the Guoneng Tibet lithium project’s BOO model, which delivers recurring processing fees and lithium sales revenue share, with significant profit upside upon permit approval; and (2) surging multi-product demand in life sciences—from weight-loss drugs to oligonucleotide therapeutics—especially export growth in consumable-grade resins driven by overseas clients. On valuation, a 39% EPS CAGR versus a current P/E of ~20x represents a notable 'value gap.' UBS believes the recent share price pullback offers an attractive entry window.

Risks

• Resin refill demand may fall short of expectations, affecting recurring revenue
• Rising raw material costs could compress gross margins
• Overseas metal extraction projects may be delayed due to stricter local regulations
• Global economic recession could dampen downstream demand
• Risk of delays in completing existing lithium extraction projects
• Client acquisition in new areas (life sciences, environmental protection, ultrapure water) may lag expectations
• Products may face import bans by certain foreign governments

What to watch

• Approval progress of the Guoneng Tibet lithium extraction project production license
• Lithium price trends and actual production/sales realization from the Guoneng project
• Actual sales growth rates of oligonucleotide and weight-loss drug SPSC in the life sciences segment
• Latest developments on overseas M&A or production base expansion